Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasm Metastasis 1Breast Neoplasms 1

Interventions

Trastuzumab 9Capecitabine 7trastuzumab deruxtecan 6Paclitaxel 6Fulvestrant 6pertuzumab 5eribulin 5Gemcitabine 4Cyclophosphamide 4sacituzumab govitecan 3Vinorelbine 3Doxorubicin 3Docetaxel 3Ado-Trastuzumab Emtansine 3130-nm albumin-bound paclitaxel 3selpercatinib 2ribociclib 2palbociclib 2olaparib 2larotrectinib 2exemestane 2abemaciclib 2Fluorouracil 2Epirubicin 2Carboplatin 2ulixertinib 1tucatinib 1trastuzumab biosimilar HLX02 1trametinib 1taxane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Breast Neoplasms × Imlunestrant × Clear all
NCT04975308 2025-07-11

EMBER-3

Eli Lilly and Company

Phase 3 Active not recruiting
874 enrolled 29 charts 1 FDA
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡